In summary, PDK1 inhibitor GSK-470 in combination with dual mTORC1/C2 inhibitor PP242 shows significant synergistic antimyeloma effects regardless of the PTEN status in MM cells, providing the framework for clinical trials of combined therapy to improve patient outcome in MM. Here, PDK1 is linked to Miyoshi myopathy.